MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$63,693K
Net Income
$48,508K
Net Profit Margin
76.16%
EPS
$2.22
Unit: Thousand (K) dollars
Revenue Breakdown
Filspari
Material Sales Captisol
Kyprolis
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues and income
63,693
51,722
23,455*
115,461
Cost of captisol
3,214
3,273
4,487*
3,801
Amortization of intangibles
8,097
8,097
8,176*
8,097
Research and development
14,668
2,148
39,803*
21,019
General and administrative
29,123
20,836
19,518*
28,446
Financial royalty assets impairment
-
-
6,197*
0
Fair value adjustments to partner program derivatives
0
0
665*
833
Total operating costs and expenses
55,102
34,354
77,515*
60,530
Gain on sale of pelican
-
-
0*
-
Operating income (gain)
8,591
17,368
-54,060*
54,931
Gain (loss) from short-term investments
11,754
3,869
5,328*
7,798
Loss (gain) from change in fair value of equity-method investments and other investments
35,727
-49,229
-23,160*
75,887
Interest income
7,298
6,655
5,417*
3,874
Interest expense
1,748
1,747
1,621*
910
Other non-operating expense, net
2,682
-1,175
-1,482*
-443
Total non-operating income (expenses), net
55,713
-41,627
-15,519*
86,206
Income (gain) before income taxes
64,304
-24,259
-69,580*
141,137
Income tax (expense) benefit
15,796
-10,914
-10,853*
23,864
Net income (loss) from continuing operations
-
-
-58,727
-
Net income (gain)
48,508
-13,345
-58,727
117,273
Basic EPS
2.42
-0.67
-3.073
5.99
Diluted EPS
2.22
-0.67
-2.889
5.68
Basic Average Shares
20,063,000
19,883,000
19,109,000
19,578,000
Diluted Average Shares
21,837,000
19,883,000
20,327,000
20,629,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Filspari
$13,567K
(106.25%↑ Y/Y)
Kyprolis
$7,044K
(-19.98%↓ Y/Y)
Royalty Intangible
Other
$4,269K
(-21.42%↓ Y/Y)
Intangible Ohtuvayre
$4,144K
Rylaze
$3,201K
(11.77%↑ Y/Y)
Capvaxive
$2,316K
Teriparatide Injection
$1,470K
(-36.03%↓ Y/Y)
Vaxneuvance
$1,351K
(-48.88%↓ Y/Y)
QARZIBA
$6,150K
(4.50%↑ Y/Y)
Financial Ohtuvayre
Inventors
$3,294K
Financial Royalty Other
$1,226K
(186.45%↑ Y/Y)
Intangible Royalty Assets
$37,362K
(24.19%↑ Y/Y)
Financial Royalty Assets
$10,670K
(69.02%↑ Y/Y)
Contract And Revenue
Income Other
$5,000K
(391.64%↑ Y/Y)
Contract Revenue
$2,683K
Royalty
$48,032K
(31.97%↑ Y/Y)
Material Sales Captisol
$7,978K
(-3.73%↓ Y/Y)
Contract Revenue And
Other Income
$7,683K
(161.06%↑ Y/Y)
Loss (gain) from
change in fair value of...
$35,727K
Gain (loss) from
short-term investments
$11,754K
(1151.76%↑ Y/Y)
Interest income
$7,298K
(350.22%↑ Y/Y)
Other non-operating
expense, net
$2,682K
(95.48%↑ Y/Y)
Total revenues and
income
$63,693K
(33.73%↑ Y/Y)
Total non-operating
income (expenses), net
$55,713K
(1904.79%↑ Y/Y)
Operating income (gain)
$8,591K
(1.74%↑ Y/Y)
Interest expense
$1,748K
(51.60%↑ Y/Y)
Total operating costs
and expenses
$55,102K
(40.63%↑ Y/Y)
Income (gain) before
income taxes
$64,304K
(472.97%↑ Y/Y)
General and
administrative
$29,123K
(44.35%↑ Y/Y)
Research and development
$14,668K
(123.36%↑ Y/Y)
Amortization of intangibles
$8,097K
(-1.95%↓ Y/Y)
Cost of captisol
$3,214K
(10.56%↑ Y/Y)
Net income (gain)
$48,508K
(900.78%↑ Y/Y)
Income tax (expense)
benefit
$15,796K
(147.74%↑ Y/Y)
Buy us a coffee
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)